We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Mild to moderate Alzheimer dementia with insufficient neuropathological changes.
- Authors
Serrano‐Pozo, Alberto; Qian, Jing; Monsell, Sarah E.; Blacker, Deborah; Gómez‐Isla, Teresa; Betensky, Rebecca A.; Growdon, John H.; Johnson, Keith A.; Frosch, Matthew P.; Sperling, Reisa A.; Hyman, Bradley T.
- Abstract
Recently, ∼16% of participants in an anti-Aβ passive immunotherapy trial for mild-to-moderate Alzheimer disease (AD) had a negative baseline amyloid positron emission tomography (PET) scan. Whether they have AD or are AD clinical phenocopies remains unknown. We examined the 2005-2013 National Alzheimer's Coordinating Center autopsy database and found that ∼14% of autopsied subjects clinically diagnosed with mild-to-moderate probable AD have no or sparse neuritic plaques, which would expectedly yield a negative amyloid PET scan. More than half of these 'Aβ-negative' subjects have low neurofibrillary tangle Braak stages. These findings support the implementation of a positive amyloid biomarker as an inclusion criterion in future anti-Aβ drug trials. Ann Neurol 2014;75:597-601
- Publication
Annals of Neurology, 2014, Vol 75, Issue 4, p597
- ISSN
0364-5134
- Publication type
Article
- DOI
10.1002/ana.24125